Skip to main content

ZyVersa Therapeutics, Inc

Monday, February 26, 2024
Multiple Therapeutics
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with renal or inflammatory diseases who have significant unmet medical needs. Our development pipeline includes clinical stage Cholesterol Efflux MediatorTM VAR 200 in development to alleviate damaging accumulation of cholesterol and lipids in the kidneys’ filtration system. The lead indication is treatment of rare kidney disease, focal segmental glomerulosclerosis. VAR 200 has potential to treat other kidney diseases, including Alport syndrome and diabetic kidney disease. ZyVersa’s pipeline also includes proprietary inflammasome ASC inhibitor IC 100 that blocks initiation and perpetuation of damaging inflammation associated with a multitude of inflammatory diseases. IC 100 has potential to treat many different CNS and other inflammatory diseases. For more information, please visit
Steve Glover, Chairman and CEO - ZyVersa Therapeutics, Inc




United States


CEO/Top Company Official

Steve Glover, Chairman and CEO

Lead Product in Development

Cholesterol Efflux Mediator VAR 200 for renal disease.

Development Phase of Primary Product

Phase II

Number Of Unlicensed Products

None. Our two development products were licensed from University of Miami.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.